Bioarctic Says Global License Agreement With Bristol Myers Squibb For Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance And Closing

Reuters
20 Feb
Feb 20 (Reuters) - BioArctic AB ::
*BIOARCTIC'S GLOBAL LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB FOR PYROGLUTAMATE-AMYLOID-BETA ANTIBODY PROGRAM EFFECTIVE AFTER ANTITRUST CLEARANCE AND CLOSING
*BIOARCTIC AB - TO RECEIVE $100 MILLION UPFRONT PAYMENT
*BIOARCTIC AB - AGREEMENT INCLUDES UP TO $1.25 BILLION IN MILESTONES
*BIOARCTIC AB - RETAINS OPTION TO CO-COMMERCIALIZE IN NORDIC REGION

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 20-FEB-202505:30:12.507 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10